Drug · FAERS side-effect profile with label screen

Halobetasol Propionate and Tazarotene side effects: what 198 FDA adverse event reports show

Halobetasol Propionate And Tazarotene · 9 reaction terms · 103 drug–reaction co-reports · data 2026-09-14

Drug class

Corticosteroid

FDA label, Indications wording of the closest related product

Label matched

Halobetasol Propionate (Halobetasol Propionate)

closest FDA label found for this product string; brand list suppressed because the label is a related product, not an exact match

Who reports

198 reports · 33% serious · 1 with death outcome · 66% female

openFDA FAERS counts, all years, deduplication not applied

Used for

Halobetasol Propionate Topical Foam is indicated for the topical treatment of plaque psoriasis in patients 12 years of age and older. Halobetasol Propionate Topical Foam is a corticosteroid indicated for the topical treatment of plaque psoriasis in patients twelve (12) years of age and older. ( 1 )

FDA label, Indications and Usage

What it is

Halobetasol Propionate Topical Foam is a hydroethanolic aerosol foam that contains a corticosteroid, halobetasol propionate.

FDA label, Description section

Boxed warning

None in the current label

How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 6 strongest signals

Labeled adverse reaction 1Labeled (related wording) 2Likely indication confounding 1Not in label — unassessed 2

What the badges mean

Labeled adverse reaction The exact term appears in the label's warnings or adverse-reactions sections: a known, expected effect. The FAERS signal confirms the label rather than discovering anything.
Labeled (related wording) The label describes this effect under different wording (e.g. 'neutropenia' for 'neutrophil count decreased'). Treated as known.
Likely indication confounding The term appears in the label's indications: reports probably describe the disease being treated (or its progression), not a drug effect. Classic confounding by indication.
Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only and flags pairs whose reports are unusually skewed by sex or come mostly from consumers rather than clinicians. 3 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show: hide coding/lab/outcome terms hide indication terms unlabeled only hide PRR-only

Reaction	Reports	PRR 95% CI · ROR · χ²/p	EBGM EB05 · IC025	Label screen	Serious-only & strata	Trial cross-check
Application site irritation	8	68.1 34.5–134.3ROR 70.9 · χ² 464 / p 3e-103	59.0 EB05 32.0 · IC025 +2.6 3/3 methods agree	Labeled (related wording) related wording	–	no trial data cached
Application site pain	10	48.1 26.3–88.0ROR 50.6 · χ² 416 / p 1e-92	44.3 EB05 25.7 · IC025 +2.8 3/3 methods agree	Labeled adverse reaction exact term	serious n=1	no trial data cached
Psoriasis	50	40.5 31.9–51.5ROR 53.9 · χ² 1,899 / p <1e-300	39.9 EB05 31.5 · IC025 +4.4 3/3 methods agree	Likely indication confounding term in indications; also in warnings	serious PRR 61.2	no trial data cached
Application site erythema	8	32.2 16.3–63.5ROR 33.5 · χ² 212 / p 3e-48	29.9 EB05 16.0 · IC025 +2.3 3/3 methods agree	Labeled (related wording) related wording	serious n=1	no trial data cached
Skin burning sensation	10	14.9 8.1–27.2ROR 15.6 · χ² 116 / p 2e-27	13.2 EB05 6.5 · IC025 +2.1 3/3 methods agree	Not in label — unassessed	serious PRR 59.6	no trial data cached
Dermatitis atopic	6	12.7 5.8–28.0ROR 13.1 · χ² 54 / p 1e-13	9.1 EB05 3.7 · IC025 +1.3 3/3 methods agree	Not in label — unassessed	–	no trial data cached

Trial evidence (ClinicalTrials.gov)

Trial cross-check not yet run for this drug (ClinicalTrials.gov pull covers the 800 most-reported drugs first).

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

Reaction	Reports	PRR 95% CI · ROR · χ²/p	EBGM EB05 · IC025	Label screen	Serious-only & strata	Trial cross-check
Psoriasis	50	40.5 31.9–51.5ROR 53.9 · χ² 1,899 / p <1e-300	39.9 EB05 31.5 · IC025 +4.4 3/3 methods agree	Likely indication confounding term in indications; also in warnings	serious PRR 61.2	no trial data cached
Skin burning sensation	10	14.9 8.1–27.2ROR 15.6 · χ² 116 / p 2e-27	13.2 EB05 6.5 · IC025 +2.1 3/3 methods agree	Not in label — unassessed	serious PRR 59.6	no trial data cached
Application site pain	10	48.1 26.3–88.0ROR 50.6 · χ² 416 / p 1e-92	44.3 EB05 25.7 · IC025 +2.8 3/3 methods agree	Labeled adverse reaction exact term	serious n=1	no trial data cached
Application site erythema	8	32.2 16.3–63.5ROR 33.5 · χ² 212 / p 3e-48	29.9 EB05 16.0 · IC025 +2.3 3/3 methods agree	Labeled (related wording) related wording	serious n=1	no trial data cached
Application site irritation	8	68.1 34.5–134.3ROR 70.9 · χ² 464 / p 3e-103	59.0 EB05 32.0 · IC025 +2.6 3/3 methods agree	Labeled (related wording) related wording	–	no trial data cached
Dermatitis atopic	6	12.7 5.8–28.0ROR 13.1 · χ² 54 / p 1e-13	9.1 EB05 3.7 · IC025 +1.3 3/3 methods agree	Not in label — unassessed	–	no trial data cached
Application site pruritus	4	18.7 7.1–49.2ROR 19.0 · χ² 50 / p 6e-13	12.7 EB05 3.6 · IC025 +0.9 3/3 methods agree	Labeled (related wording) related wording	–	no trial data cached
Squamous cell carcinoma	4	45.0 17.0–118.6ROR 45.9 · χ² 131 / p 1e-30	36.1 EB05 13.1 · IC025 +1.2 3/3 methods agree	Not in label — unassessed	serious PRR 80.0	no trial data cached
Application site rash	3	23.0 7.5–70.8ROR 23.4 · χ² 43 / p 3e-11	13.8 EB05 3.0 · IC025 +0.4 3/3 methods agree	Labeled (related wording) related wording	–	no trial data cached

Unlabeled candidate signals

Every screened signal with n ≥ 20 was either labeled, an indication term, or an artifact pattern — no unlabeled candidate stood out in the top signals.

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of Halobetasol Propionate and Tazarotene?

In FDA FAERS, the most frequently co-reported reaction terms for Halobetasol Propionate and Tazarotene are psoriasis, skin burning sensation, application site pain, application site erythema, application site irritation, dermatitis atopic. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does Halobetasol Propionate and Tazarotene have an FDA boxed warning?

No. The FDA label retrieved for Halobetasol Propionate and Tazarotene has no boxed warning; see the label's Warnings and Precautions for the recognised risks.

Do FAERS signals prove that Halobetasol Propionate and Tazarotene causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

FDA label via openFDA (set ID 24c41e6d-a314-4984-b45f-e5aa1fffa9b6, effective 20231130; matched on openfda.generic_name.exact:"HALOBETASOL PROPIONATE")
Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA count= aggregation, field patient.drug.openfda.generic_name.exact, 9 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction
Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
Seriousness and sex counts from openFDA count=serious, patient.patientsex, seriousnessdeath

Page generated 2026-10-08. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.